Shahid Siddiqui, MD
Cardiology · San Jose, CANPI 1922005636
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,663 of the $3,424 with a category attached, or 77.8%. It is spread thinly across 23 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $889 and has fallen 57.7% since, to $376 in 2025.
Across 151 payments — averaging $22.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$501
- Novartis$388
- Boston Scientific$274
- Boehringer Ingelheim$269
- Pfizer$213
- Abbott$192
- plus $2K from 17 others
What the payments were for
- Grants$552%
- Travel & lodging$33910%
- Food & beverage$2,66378%
- Education$36811%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 8 | $501 |
| Novartis | 19 | $388 |
| Boston Scientific | 11 | $274 |
| Boehringer Ingelheim | 38 | $269 |
| Pfizer | 11 | $213 |
| Abbott | 8 | $192 |
| E.r. Squibb & Sons, L.L.C. | 8 | $191 |
| Amgen | 7 | $166 |
| Abiomed | 1 | $147 |
| Novo Nordisk | 8 | $146 |
| Merck | 7 | $134 |
| Johnson & Johnson | 7 | $134 |
| AstraZeneca | 3 | $133 |
| Edwards Lifesciences | 2 | $128 |
| Baxter Healthcare | 4 | $93 |
| Penumbra, Inc. | 1 | $88 |
| Bardy Diagnostics, Inc. | 2 | $82 |
| Regeneron | 1 | $33 |
| Heartflow, Inc. | 1 | $27 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $26 |
| Philips North America LLC | 1 | $24 |
| Bayer | 1 | $20 |
| Biotronik Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,424 in reported general payments places this provider in the 75th percentile of 156 cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 253 | $357,639 |
| XareltoRivaroxaban | 51 | $76,267 |
| EntrestoSacubitril/Valsartan | 41 | $45,022 |
| BrilintaTicagrelor | 39 | $29,966 |
| JardianceEmpagliflozin | 11 | $7,339 |
| Metoprolol Succinate | 270 | $5,376 |
| Atorvastatin Calcium | 282 | $3,223 |
| Ranolazine ErRanolazine | 20 | $3,122 |
| ClopidogrelClopidogrel Bisulfate | 184 | $2,562 |
| Rosuvastatin Calcium | 91 | $1,894 |
| Losartan Potassium | 117 | $1,370 |
| Metoprolol Tartrate | 125 | $1,163 |
| Amlodipine Besylate | 211 | $957 |
| SotalolSotalol Hcl | 45 | $950 |
| Flecainide Acetate | 15 | $949 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $213 | $357,639253 claims |
| Johnson & JohnsonXarelto | $134 | $76,26751 claims |
| NovartisEntresto | $388 | $45,02241 claims |
| AstraZenecaBrilinta | $133 | $29,96639 claims |
| Boehringer IngelheimJardiance | $269 | $7,33911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 156 cardiology providers in California.
Other cardiology in San Jose
- Munawar AlaviSan Jose$2K
- Norman LeporBeverly Hills$1.9M
- Sanjay KaulLos Angeles$1.1M
- Ramtin AgahMountain View$361K
- Jamshid MaddahiLos Angeles$59K
- Bipin JoshiFresno$51K
- Anil ShahSanta Ana$49K
- Thomas KimSanta Ana$47K
- Hooman MadyoonLos Angeles$24K
- Lakhjit SandhuFresno$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.